DK0567585T3 - Hepatisk vækstfaktorreceptor er met-protoonkogenet - Google Patents

Hepatisk vækstfaktorreceptor er met-protoonkogenet

Info

Publication number
DK0567585T3
DK0567585T3 DK92905178T DK92905178T DK0567585T3 DK 0567585 T3 DK0567585 T3 DK 0567585T3 DK 92905178 T DK92905178 T DK 92905178T DK 92905178 T DK92905178 T DK 92905178T DK 0567585 T3 DK0567585 T3 DK 0567585T3
Authority
DK
Denmark
Prior art keywords
oncogene
growth factor
metrotone
factor receptor
hepatic growth
Prior art date
Application number
DK92905178T
Other languages
Danish (da)
English (en)
Inventor
Donald P Bottaro
Jeffrey S Rubin
Donna Faletto
Andrew M-L Chan
Woude George F Vande
Stuart A Aaronson
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of DK0567585T3 publication Critical patent/DK0567585T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
DK92905178T 1991-01-18 1992-01-15 Hepatisk vækstfaktorreceptor er met-protoonkogenet DK0567585T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/642,971 US5648273A (en) 1989-12-27 1991-01-18 Hepatic growth factor receptor is the MET proto-oncogene
PCT/US1992/000071 WO1992013097A1 (en) 1991-01-18 1992-01-15 Hepatic growth factor receptor is the met proto-oncogene

Publications (1)

Publication Number Publication Date
DK0567585T3 true DK0567585T3 (da) 1999-12-13

Family

ID=24578815

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92905178T DK0567585T3 (da) 1991-01-18 1992-01-15 Hepatisk vækstfaktorreceptor er met-protoonkogenet

Country Status (11)

Country Link
US (1) US5648273A (ja)
EP (1) EP0567585B1 (ja)
JP (2) JP2598362B2 (ja)
AT (1) ATE182902T1 (ja)
AU (1) AU652031B2 (ja)
CA (2) CA2099865C (ja)
DE (1) DE69229720T2 (ja)
DK (1) DK0567585T3 (ja)
ES (1) ES2136082T3 (ja)
GR (1) GR3031381T3 (ja)
WO (1) WO1992013097A1 (ja)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362716A (en) * 1989-12-27 1994-11-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines
US5871959A (en) * 1989-12-27 1999-02-16 The United States Of America As Represented By The Department Of Health And Human Services Method of producing hepatocycte growth factor/scatter factor and related cell lines
EP0520158A1 (en) * 1991-05-10 1992-12-30 PHARMACIA S.p.A. Truncated forms of the hepatocyte growth factor (HGF) receptor
EP0662130B1 (en) * 1992-09-18 1997-11-26 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES A method of producing hepatocyte growth factor and a cell line
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
AU7157896A (en) * 1995-09-12 1997-04-01 Children's Hospital Medical Center Of Northern California Cystic fibrosis therapy
US5866329A (en) * 1995-09-27 1999-02-02 Demetriou; Achilles A. Method and probe for detection of gene associated with liver neoplastic disease
AU7389496A (en) * 1995-10-05 1997-04-28 Genentech Inc. Methods and compositions for treating vascular stenosis
AU7254896A (en) * 1995-10-05 1997-04-28 Genentech Inc. Improved angiogenesis using hepatocyte growth factor
AU729029B2 (en) * 1996-07-03 2001-01-25 Genentech Inc. Hepatocyte growth factor receptor agonists and uses thereof
JP4006058B2 (ja) * 1997-03-11 2007-11-14 第一三共株式会社 多臓器不全予防及び／又は治療剤
ATE344050T1 (de) * 1997-03-14 2006-11-15 Daiichi Seiyaku Co Verwendung von tcf-ii zur behandlung von durch krebs verursachtem gewichtsverlust, anaemie und tnf-erhöhung
ES2295198T3 (es) * 2000-08-28 2008-04-16 Damavand Wound Ab Los efectos sinergicos de hgf y tratamiento antibacteriano.
US20030118585A1 (en) * 2001-10-17 2003-06-26 Agy Therapeutics Use of protein biomolecular targets in the treatment and visualization of brain tumors
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
DK1687636T3 (da) * 2003-09-29 2009-05-11 Peas Inst Ab Hurtig bestemmelse af forskellige former for hepatocytvækstfaktor (HGF) i legemsvæsker
AU2004290070A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
MX2007001470A (es) 2004-08-05 2007-03-26 Genentech Inc Antagonistas anti-cmet humanizados.
WO2006074397A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Cripto binding molecules
WO2006105511A1 (en) 2005-03-31 2006-10-05 The General Hospital Corporation Monitoring and modulating hgf/hgfr activity
RU2403261C2 (ru) 2005-04-15 2010-11-10 Дженентек, Инк. Варианты бета-цепи hgf
EP1952826A4 (en) * 2005-10-24 2011-05-18 Fujifilm Ri Pharma Co Ltd DIAGNOSTIC AGENT AND THERAPEUTIC AGENT FOR DISEASES RELATED TO THE HEPATOCYTE GROWTH FACTOR RECEPTOR
EP1957541A2 (en) * 2005-11-21 2008-08-20 Laboratoires Serono SA Compositions and methods of producing hybrid antigen binding molecules and uses thereof
KR101671378B1 (ko) * 2009-10-30 2016-11-01 삼성전자 주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
CN103003307B (zh) 2010-03-10 2017-08-11 根马布股份公司 抗c‑MEt的单克隆抗体
AU2011274423B2 (en) 2010-07-09 2016-02-11 Bioverativ Therapeutics Inc. Chimeric clotting factors
EP2635602B1 (en) 2010-11-03 2016-09-07 Argen-X Nv Anti c-met antibodies
MX2013014687A (es) 2011-06-30 2014-02-17 Genentech Inc Formulaciones de anticuerpo anti-c-met.
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
EP2773660A2 (en) 2011-11-03 2014-09-10 Argen-X B.V. Chimeric human-camel antigens and their use
NZ626620A (en) 2012-01-10 2016-07-29 Biogen Ma Inc Enhancement of transport of therapeutic molecules across the blood brain barrier
EP2968498A4 (en) 2013-03-15 2016-09-07 Biogen Ma Inc PREPARATIONS CONTAINING FACTOR IX POLYPEPTIDE
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
CN115181778A (zh) 2015-02-04 2022-10-14 百时美施贵宝公司 选择治疗性分子的方法
MX2017010066A (es) 2015-02-04 2017-11-01 Hoffmann La Roche Oligomeros antisentido de tau y usos de los mismos.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5030565A (en) * 1983-08-17 1991-07-09 Scripps Clinic And Research Foundation Polypeptide-induced monoclonal receptors to protein ligands

Also Published As

Publication number Publication date
CA2176620A1 (en) 1992-07-19
JP2598362B2 (ja) 1997-04-09
GR3031381T3 (en) 2000-01-31
CA2099865A1 (en) 1992-07-19
CA2176620C (en) 2001-04-24
JPH06505968A (ja) 1994-07-07
AU652031B2 (en) 1994-08-11
JP3387745B2 (ja) 2003-03-17
AU1273892A (en) 1992-08-27
EP0567585B1 (en) 1999-08-04
US5648273A (en) 1997-07-15
WO1992013097A1 (en) 1992-08-06
DE69229720T2 (de) 2000-04-27
EP0567585A4 (ja) 1994-08-03
EP0567585A1 (en) 1993-11-03
CA2099865C (en) 1997-11-25
ATE182902T1 (de) 1999-08-15
DE69229720D1 (de) 1999-09-09
ES2136082T3 (es) 1999-11-16
JPH09127107A (ja) 1997-05-16

Similar Documents

Publication Publication Date Title
DK0567585T3 (da) Hepatisk vækstfaktorreceptor er met-protoonkogenet
DK464478A (da) Fremgangsmaade til fremstilling af 3-substituerede 6-(1'hydroxyethyl)-m-oxo-1-azabicyclo(3,2,0)hept-2-en-2-carboxylsyrer eller derivater deraf
NO904984L (no) Fremgangsmaate for fremstilling av pyridazin-derivater.
NO870560D0 (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat
NO178858C (no) Analogifremgangsmåte for fremstilling av substituerte 4-fenyl-4-piperidinkarboksamider med både lokal anestetisk og analgetisk effekt
NO822704L (no) Fremgangsmaate for fremstilling av insulinderivater.
FR2613937B1 (fr) Ligands specifiques de recepteurs d'hormones steroides utiles pour la therapie ciblee ou l'imagerie medicale notamment du cancer
NL7805847A (nl) Nieuwe, op de 11-plaats gesubstitueerde 5.11-dihydro- -6h-pyrido/2.3-b//1.4/-benzodiazepin-6-on, werkwijzen ter bereiding daarvan, en preparaten, die deze verbin- dingen bevatten.
NO901423L (no) Fremgangsmaate for fremstilling av selektive adenosinreseptormidler.
MD940152A (ro) Compoziţie farmaceutică pentru tratarea infecţiilor şi bolilor, provocate de virusul hepatitei V (HBV)
NO901631D0 (no) Fremgangsmaate for fremstilling av 2-substituerte n,n'-ditrimetoksybenzoyl-piperaziner.
NO900297D0 (no) Fremgangsmaate for fremstilling av vaeskeformige preparaterinneholdende piperidinoalkanolderivater.
NO167807C (no) Analogifremgangsmaate til fremstilling av 3',4'-dinitrogensubstituerte epipodofyllotoksinglukosidderivater.
NO901690L (no) Fremgangsmaate til fremstilling av substituerte azetidinylisotiazolpyridon-derivater.
NO905364L (no) Fremgangsmaate ved fremstilling av alkansyrederivater.
NL7808124A (nl) Nieuwe dibenzo( d,g)( 1,3,6)dioxazocine derivaten, werkwijze voor het bereiden daarvan alsmede voornoemde derivaten bevattende farmaceutische preparaten.
NL7800001A (nl) Werkwijze voor de bereiding van nieuwe chromoon- derivaten en de toepassing hiervan als genees- middel tegen hartziekten.
NO900969D0 (no) Fremgangsmaate for fremstilling av anilin-derivat.
NL187168C (nl) 3 beta-oxygesubstitueerde-18 beta-olean-30-carboxyderivaten, werkwijze ter bereiding daarvan en farmaceutische preparaten welke een of meer van deze verbindingen bevatten.
Russell et al. Challenge Virus Resistance and Interferon Produced in BS-G-1 Cells By Dengue Virus
JPS5432481A (en) Carbostyril derivatives
JPS53112883A (en) Carbostyril derivative
ES518725A0 (es) Procedimiento de preparacion de nuevos derivados del azabiciclo (3.2.0) heptano.
NO144411C (no) Anordning for gradering av biologisk vaeslke, saerlig blod, etter molekylvekt.
LU79638A1 (fr) Procede de preparation de derives semi-synthetiques de la 4"-sulfonylamino-oleandomycine